Volume 89, Issue 1 pp. 115-117
Correspondence
Free Access

Flow cytometry analyses reveal association between Lu/BCAM adhesion molecule and osteonecrosis in sickle cell disease

Julien Picot

Julien Picot

Institut National de la Transfusion Sanguine, Paris, France, F-75739

Inserm, UMR_S665, Paris, France, F-75739

Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Laboratory of Excellence GR-Ex, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

Search for more papers by this author
Christel Goudot

Christel Goudot

Institut National de la Transfusion Sanguine, Paris, France, F-75739

Inserm, UMR_S665, Paris, France, F-75739

Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Laboratory of Excellence GR-Ex, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

Search for more papers by this author
Jugurtha Berkenou

Jugurtha Berkenou

Unité des Maladies Génétiques du Globule Rouge, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

Search for more papers by this author
Frédéric Galacteros

Frédéric Galacteros

Unité des Maladies Génétiques du Globule Rouge, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

Search for more papers by this author
Yves Colin

Yves Colin

Institut National de la Transfusion Sanguine, Paris, France, F-75739

Inserm, UMR_S665, Paris, France, F-75739

Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Laboratory of Excellence GR-Ex, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

Search for more papers by this author
Pablo Bartolucci

Pablo Bartolucci

Institut National de la Transfusion Sanguine, Paris, France, F-75739

Inserm, UMR_S665, Paris, France, F-75739

Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Laboratory of Excellence GR-Ex, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

P.B. and C.L.V.K. contributed equally to this work.

Search for more papers by this author
Caroline le van Kim

Corresponding Author

Caroline le van Kim

Institut National de la Transfusion Sanguine, Paris, France, F-75739

Inserm, UMR_S665, Paris, France, F-75739

Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Laboratory of Excellence GR-Ex, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France, F-94000

Correspondence to: Caroline Le Van Kim, UMR_S665, INTS, 6 rue Alexandre Cabanel 75015, Paris, France. E-mail: [email protected]Search for more papers by this author
First published: 03 October 2013
Citations: 6

Julien Picot is currently at GIP Genopole, Evry, France F-91030.

Christel Goudot is currently at Institut Jacques Monod, Paris, France F-75205.

Pablo Bartolucci is currently at Unité des Maladies Génétiques du Globule Rouge, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France F-94000.

Conflict of interest: Nothing to report.

To the Editor

To identify relevant biomarkers of sickle cell disease (SCD), we determined by flow cytometry the expression of 10 adhesion membrane proteins present in reticulocytes and of eight adhesion membrane proteins present in red blood cells (RBCs; CD36 and CD49d are expressed in reticulocytes but not expressed in mature RBCs).

The study was conducted with a cohort of 68 homozygous SCD adult patients (SS or S beta-thal), untreated by hydroxycarbamide, and at basal steady state defined as a visit >1 month after an acute clinical event and >3 months after blood transfusion. Patients were categorized according to the absence versus presence of one out of eight clinical complications: renal dysfunction (defined as proteinuria ≥0.3 g/L or estimated glomerular filtration rates <80 mL/min) (chronic); leg ulcer (chronic); priapism (acute); pulmonary arterial hypertension (PAHT) confirmed by right heart catheterization (chronic); cerebral vasculopathy confirmed by magnetic resonance imaging (chronic); history of acute chest syndrome (ACS; acute); retinopathy (chronic); aseptic osteonecrosis confirmed by radiography or magnetic resonance imaging (chronic). Some patients exhibiting more than one complication belonged to several groups. Comparisons were made between symptomatic versus asymptomatic patients included in glomerulopathy group (13 vs. 55), in leg ulcer group (9 vs. 59), in priapism group (14 vs. 24 (men only)), in PAHT group (5 vs. 63), in cerebral vasculopathy group (6 vs. 62), in ACS group (29 vs. 39), in retinopathy group (26 vs. 42), and in aseptic osteonecrosis of hip and/or shoulder group (18 vs. 50).

When considering both the percentage of positive cells and the mean fluorescence intensity on both reticulocytes and mature RBCs, only CD239 (Lu/BCAM), the unique erythroid laminin α-5 receptor 1, 2 was found associated with a clinical complication. CD239 expression was significantly higher in reticulocytes and mature RBCs from patients with osteonecrosis than in those from patients exhibiting other complications (Table 1). Similarly, a higher percentage of CD239 positive reticulocytes and RBCs were observed in patients with osteonecrosis. It is noteworthy that the ligand of CD239, α-5 laminin, is abundant in bone marrow 4, where osteonecrosis takes place. CD239 is involved in abnormal adhesion of RBCs from SCD patients to components of the vascular wall and may participate to the occurrence of vaso occlusive crisis (VOC) 5.

Table 1. Expression of Erythroid Adhesion Molecules from SS Patients Classified into Eight Groups of Complications
Complications Patients % MFI % MFI % MFI % MFI % MFI
Reticulocytes CD44 CD47 CD99 CD108 CD147
Total n = 68 95.82 9,580 100.00 41,873 75.00 2,461 53.52 537 98.59 10,285
Glomerulopathy n = 13 91.07 9,921 100.00 43,721 81.77 2,199 47.40 569 100.00 6,088
Leg ulcer n = 9 91.84 7,949 93.16 39,795 73.14 3,752 49.04 502 97.28 12,721
Pulmonary arterial hypertension n = 5 97.86 9,430 97.75 49,366 74.16 2,615 41.82 604 100.00 12,631
Cerebral vasculopathy n = 6 87.05 9,448 100.00 41,334 73.33 3,528 71.31 606 100.00 8,133
Acute chest syndrome n = 29 91.89 7,883 97.73 32,701 75.00 2,938 43.16 500 98.65 10,285
Retinopathy n = 26 94.33 9,676 98.88 39,061 72.84 2,499 53.52 568 99.56 11,508
Aseptic osteonecrosis n = 18 91.19 9,877 100.00 46,104 73.24 3,115 49.95 493 98.51 12,964
Total men n = 24 92.86 9,396 100.00 39,868 75.00 2,352 46.43 532 95.36 9,901
Priapism n = 14 90.63 11,522 94.96 41,250 74.58 4,301 51.80 558 99.59 12,632
CD151 CD239 CD242 CD36 CD49d
Total n = 68 11.68 805 89.26 6,192 100.00 2,277 8.77 1133 12.50 880
Glomerulopathy n = 13 9.70 955 90.30 5,919 100.00 1,881 12.20 797 15.38 903
Leg ulcer n = 9 18.75 554 91.03 7,182 100.00 2,633 12.83 1104 13.46 903
Pulmonary arterial hypertension n = 5 16.85 440 92.74 6,945 100.00 2,724 12.83 1436 6.67 889
Cerebral vasculopathy n = 6 17.52 616 93.22 6,097 100.00 2,907 12.45 1065 10.79 847
Acute chest syndrome n = 29 9.46 805 90.30 5,919 100.00 2,074 10.34 1064 10.43 855
Retinopathy n = 26 9.23 751 93.10 6,465 100.00 2,191 8.03 1213 11.98 887
Aseptic osteonecrosis n = 18 13.95 831 95.54 7,613 100.00 2,310 9.99 1245 11.65 916
Total men n = 24 15.49 739 89.26 6,282 100.00 2,217 12.36 1123 13.16 829
Priapism n = 14 10.09 743 93.34 7,793 100.00 2,384 16.00 1345 16.15 989
RBC CD44 CD47 CD99 CD108 CD147
Total n = 68 91.40 5,006 91.20 41,008 41.95 978 23.80 408 91.00 6,371
Glomerulopathy n = 13 88.80 5,137 86.80 37,668 44.70 1,003 19.40 461 87.90 4,226
Leg ulcer n = 9 86.20 4,531 86.30 32,388 54.00 1,505 23.90 384 86.40 6,810
Pulmonary arterial hypertension n = 5 87.60 4,959 88.20 37,668 28.70 902 13.30 401 87.30 7,742
Cerebral vasculopathy n = 6 92.80 5,093 91.60 49,273 41.70 1,277 52.50 445 92.15 6,283
Acute chest syndrome n = 29 91.90 4,156 92.00 29,037 44.70 1,090 21.30 385 91.70 5,706
Retinopathy n = 26 90.75 4,406 89.80 32,553 44.70 1,060 25.65 423 90.95 6,548
Aseptic osteonecrosis n = 18 91.60 4,674 89.80 40,711 46.50 1,159 25.30 379 91.70 7,241
Total men n = 24 91.90 4,789 91.30 37,638 43.10 875 13.10 381 91.40 5,642
Priapism n = 14 89.05 5,006 88.35 38,251 34.75 1,410 23.50 405 88.70 6,736
CD151 CD239 CD242
Total n = 68 1.55 408 75.50 3,030 90.10 1,710
Glomerulopathy n = 13 1.70 469 72.20 3,022 83.50 1,591
Leg ulcer n = 9 2.00 417 74.30 3,037 85.40 1,992
Pulmonary arterial hypertension n = 5 3.70 337 73.70 3,207 87.30 2,111
Cerebral vasculopathy n = 6 3.10 398 83.20 3,066 92.20 2,559
Acute chest syndrome n = 29 1.30 441 76.60 3,022 90.70 1,722
Retinopathy n = 26 1.20 425 77.60 3,140 89.75 1,664
Aseptic osteonecrosis n = 18 1.35 413 83.10 4,131 91.10 1,710
Total men n = 24 1.95 415 75.45 3,175 90.90 1,761
Priapism n = 14 0.85 418 76.20 3,324 88.05 1,621
  • All patients gave their signed informed consent for the studies in accordance with the Declaration of Helsinki. Chronically transfused patients were excluded. The levels of 10 adhesion molecules in reticulocytes and 8 in RBCs were assessed by flow cytometry from frozen blood samples. Direct or indirect staining were performed using mouse monoclonal antibodies as described 3. Mean fluorescence intensities (MFI) were standardized by Flow set beads (Beckman Coulter, Villepinte, France). Analyses were performed with a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA),
  • a p < 0.05.
  • b p < 0.01.

The pathogenesis of osteonecrosis in SCD remains largely unknown, although a recent study demonstrated an association between osteonecrosis and increased RBC deformability 6. As analyses were performed in patients at steady state, i.e., at a distance from an hospitalization due to VOC, we suggest that CD239 might represent a predictive rather than a diagnosis marker of a vascular osteonecrosis. Although further longitudinal studies will be necessary to confirm this hypothesis, our results suggest that CD239 may play a role in this SCD complication, opening a new avenue of research.

Acknowledgments

The authors thank the patient for their kind participation in this study. The authors thank Eliane VERA from Centre National de Référence sur les Groupes Sanguins - Institut National de la Transfusion Sanguine for the storage and management of blood samples. This study was supported by grants from Laboratory of Excellence GR-Ex, reference ANR-11-LABX-0051. The labex GR-Ex is funded by the program “Investissements d'avenir” of the French National Research Agency, reference ANR-11-IDEX-0005-02.

  • Julien Picot1–4

  • Christel Goudot1–4

  • Jugurtha Berkenou5

  • Frédéric Galacteros5

  • Yves Colin1–4

  • Pablo Bartolucci1–4

  • Caroline le van Kim1–4*

  • 1Institut National de la Transfusion Sanguine, Paris, France F-75739

  • 2Inserm, UMR_S665, Paris, France F-75739

  • 3Université Paris Diderot, Sorbonne Paris Cité, Paris, France

  • 4Laboratory of Excellence GR-Ex

  • 5Unité des Maladies Génétiques du Globule Rouge, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France F-94000

  • P.B. and C.L.V.K. contributed equally to this work.

  • Julien Picot is currently at GIP Genopole, Evry, France F-91030.

  • Christel Goudot is currently at Institut Jacques Monod, Paris, France F-75205.

  • Pablo Bartolucci is currently at Unité des Maladies Génétiques du Globule Rouge, Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France F-94000.

  • Conflict of interest: Nothing to report.

      The full text of this article hosted at iucr.org is unavailable due to technical difficulties.